Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice
Tommaso Ceruti, Roberta Frapolli, Carmen Ghilardi, Alessandra Decio, Giulia Dellavedova, Sara Tommasi, Massimo Zucchetti, Arduino A. Mangoni · 2023
Read Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice by Tommaso Ceruti, Roberta Frapolli, Carmen Ghilardi, Alessandra Decio, Giulia Dellavedova, Sara Tommasi, Massimo Zucchetti, Arduino A. Mangoni (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10746103.txt.
Description
Tommaso Ceruti and co-authors build a lab method in 2023 to track two cancer drug compounds in mice. One compound blocks an enzyme linked to breast cancer growth, and the other is its active breakdown product. The cancer model uses human triple-negative breast cancer cells.
Their method proved accurate for measuring both compounds in blood and tumor tissue. Both were found in tissue and blood one hour after a dose, and still at low levels after a day. Neither built up over five days of dosing. Half-lives were a few hours in both blood and tumor.
Catalog record
| CREATOR | Tommaso Ceruti, Roberta Frapolli, Carmen Ghilardi, Alessandra Decio, Giulia Dellavedova, Sara Tommasi, Massimo Zucchetti, Arduino A. Mangoni |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |